An observational study in Schizophrenia Disorder, sponsored by Ole Köhler-Forsberg. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Ole Köhler-Forsberg · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Schizophrenia with a site in Denmark — 10 open to participants now, 12 under way, none of them phase 3. Schizophrenia · Denmark.
Among the 79 studies in Schizophrenia with a site in Denmark, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2025, is one of 12 observational ones, reaches primary completion later than 8 of the 11 other live ones, and was the 77th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →10 of the 79 studies in Schizophrenia with a site in Denmark are open now. Recruiting first, the newest first:
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Sites in Denmark
Ages 35–75
Nikolai Albert · Sites in Denmark
Ages 18–35
Anders Fink-Jensen, MD, DMSci · Sites in Denmark
Ages 18–70
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Sites in Denmark
Ages 18–35
University of Aarhus · Sites in Denmark
Ages 15+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 178 across 508 observational studies indexed under Schizophrenia.
Median enrollment 108 across the 67 interventional studies, 203 across the 11 observational. Of the 61 that completed or were terminated, 5 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 79 have an industry lead sponsor. The 10 most frequent:
Ole Köhler-Forsberg is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Ole Köhler-Forsberg has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
4 of the studies in Schizophrenia with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07716969Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg HospitalTOPUS - Testing an Implemented Intervention to Reduce Duration of Untreated Psychosis | 2026-12-31 |
| NCT06431009University of AarhusThe Danish Region Midt Schizophrenia Cohort | 2026-12-31 |
| NCT07082777University of AarhusRecovery in Telling Life Stories | 2027-04-01 |
| NCT07404085Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg HospitalEpigenetic Enhancement of Cognitive Training in Aging Mood and Schizophrenia Spectrum Disorder Populations | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 79 studies in Schizophrenia with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objective The objective is to recruit antipsychotic-naïve patients at the first diagnosis with a first-episode schizophrenia disorder (FES) to study ketone metabolism of the brain via PET neuroimaging. Participants will undergo PET neuroimaging at baseline before start of antipsychotic treatment and after 4-8 weeks of antipsychotic treatment including an additional clinical follow-up visit after 6 months. In addition, a healthy control group with one baseline visit will be recruited.
Study design Non-interventional neuroimaging study with pre-defined follow-up visits.
Patients Patients with a FES (ICD-10: F20) aged 18-35 years who are antipsychotic-naïve including age- and sex-matched healthy controls.
Sample size This is an observational pilot project. Currently, no studies have measured brain ketone metabolism before and after AP intake. Assuming a 50% dropout rate at follow-up, the investigators aim to recruit 22 patients to obtain 12 full datasets - a sample size commonly used in PET studies. Healthy controls will only have one study day, so no dropouts are expected - aiming at a sample size of 12 healthy controls.
Procedures Patients will be included at the first FES diagnosis. Before inclusion, an interview with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview will validate the diagnosis. At baseline and follow-up (details in the full protocol and Table 1), patients will be rated by use of the 6-item Positive and Negative Syndrome Scale (PANSS-6), the Clinical Global Impression Severity Scale (CGI-S), the Global Assessment of Functioning Scale (GAF), Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT), Fagerström Test for Nicotine Dependence (FTND), and the Calgary Depression Scale for Schizophrenia (CDSS). The Matrics Consensus Cognitive Battery (MCCB), which consists of 10 cognitive tests, will measure cognition. Heart rate, blood pressure, height, body weight, waist and hip circumference will be recorded. Patients will be treated according to clinical indication, i.e., they will receive routine clinical care at the local psychiatric hospital and participation in this study will not affect the treatment.
Follow-up Patients will be treated and followed according to normal clinical treatment guidelines at the local psychiatric hospitals, which will not be affected by participation. A re-scan will be performed after 4-8 weeks of antipsychotic treatment.
Endpoints The primary endpoints are
Risks and Safety Patients will follow treatment-as-usual at their local psychiatric hospital, with the clinicians from the local hospital being responsible for safety monitoring according to local treatment guidelines. Participation in the present study will not delay clinically indicated antipsychotic treatment. Blood sample results will be obtained from the patient's medical record (MidtEPJ) at the study visits to monitor biochemical safety parameters for medical treatment. Between follow-up visits for this study, patients will follow guideline-based safety monitoring at the local psychiatric hospital.
During the PET neuroimaging, participants will have two catheters, one arterial and one venous. Vascular puncture can result in a light degree of pain. The risk of infection is negligible.
PET: Injection of the radiotracer may cause slight pain and redness, which should rapidly resolve. The radiotracers [15O]H2O and [11C]OHB are radiolabeled versions of their naturally occurring versions, thus sharing their chemical properties. They are given in non-pharmacological doses. [18F]FDG is an analogue of glucose, given in non-pharmacological dose (\<1 nanogram). Allergic reactions have been described, but are extremely rare - it has been used routinely in the workup of cancer patients through decades. Ultimately, no pharmacologic or immunologic side effects are to be expected from the radiotracers.
The amount of radiation to healthy controls will be 4.6 mSv. Since patients have two study days, the total radiation dose to patients will be 9.2 mSv. The mean background radiation in Denmark is approximately 3 mSv per year. Thus, healthy subjects and patients will get approximately 1½ and 3 times the yearly background radiation during the study. In Denmark, the lifetime risk of lethal cancer is approximately 25%. The radioactive dose of 9.2 mSv administered to patients in this study, may increase the risk by 0.05% (from 25% to 25.05%). The radioactive dose of 4.6 mSv administered to healthy controls in this study, may increase the risk by 0.02% (from 25% to 25.02%).
Study duration 2025-2027.
Antipsychotic-naive patients with FES and healthy controls
Inclusion Criteria:
Inclusion criteria for patients with FES
Inclusion criteria for healthy controls
Exclusion Criteria:
Exclusion criteria for patients with FES
Use of an antipsychotic in the last 3 months before inclusion at a dose greater than:
4.1 Seroquel/Quetiapine 50 mg 4.2 Risperdal/Risperidone 0.5 mg
Exclusion criteria for healthy controls
Use of AP in the last 3 months before inclusion at a dose greater than:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Whole brain ketone and glucose metabolism in FES compared to healthy controls measured via PET
Time frame: At enrollment, i.e. at the baseline PET scan
Whole brain ketone and glucose metabolism in FES after antipsychotic treatment
Time frame: From baseline scan to the follow-up scan after 4-8 weeks of antipsychotic treatment
Correlation between antipsychotic response, as measured on the PANSS-6, with the change in brain ketone and glucose metabolism in patients with FES
Time frame: From baseline to follow-up scan after 4-8 weeks of antipsychotic treatment
Correlation between the MCCB with the change in brain ketone and glucose metabolism in patients with FES
Time frame: From baseline to follow-up scan after 4-8 weeks of antipsychotic treatment
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.
Of 114 non-industry observational studies under Schizophrenia, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 114. This study's planned 32 months is below that.
Counting every sponsor, half of 136 studies reached it within 47 months; a quarter within 27 and three quarters within 102.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ole Köhler-Forsberg